Johnson & Johnson's Xarelto (rivaroxaban) took a notable hit in the second quarter from the recently-implemented 70% price discount requirement for branded drugs in the Medicare Part D donut hole.
US sales for the blood thinner decreased 19.2% to $549m in the period despite an increase in Xarelto’s share of...







